Trial summary: Randomised Evaluation of COVID-19 Therapy (RECOVERY)
Site and lead:
- Manchester Royal Infirmary: Prof Simon Carley
- Wythenshawe Hospital: Dr Tim Felton
Patient group: all COVID-19 patients
- Lopinavir-Ritonavir (commonly used to treat HIV)
- Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
- Hydroxychloroquine (related to an anti-malarial drug).
Funder: Medical Research Council
Sponsor: University of Oxford
More about RECOVERY
The Randomised Evaluation of COVID Therapy (RECOVERY) trial is testing if existing or new drugs can help patients hospitalised with confirmed COVID-19.
The therapies being tested will be evaluated to see if they are safe and effective when added to the usual standard of care.
The trial has an ‘adaptive’ design, meaning it can test new therapies as they become available. The aim is for national data to be available to inform patient treatment within three months.
- Read more about RECOVERY at MFT in our website news story.
- Read more about RECOVERY on the NIHR website.